• Product NameMCC950
• Brief DescriptionInhibitors
• Purification98.30%
• Biological ActivityCP-456773, (MCC950 and CRID3), is a potent and selective cytokine release inhibitor and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. CP-456773 inhibits interleukin 1β (IL-1β) secretion and caspase 1 processing. MCC950 blocked canonical and noncanonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibited activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes. MCC950 reduced interleukin-1β (IL-1β) production in vivo and attenuated the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. MCC950 is a potential therapeutic for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases, and a tool for further study of the NLRP3 inflammasome in human health and disease.
• Target NameNOD inhibitor
• CAS No. 210826-40-7
• Calculated MW 404.48
• Formulation C20H24N2O5S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Immunology
  SMILES:CC(C)(C1=COC(=C1)S(=O)(=O)NC(=O)NC2=C3CCCC3=CC4=C2CCC4)O
  Pathways:Immunology/Inflammation; NF-κB
  Receptor:NLRP3; NLRP3
  Boling pt:
  Melting pt:
  Solubility:DMSO: 28 mg/mL
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Coll RC, et al. Nat Med. 2015 Mar;21(3):248-55.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting